Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Eli Lilly and Company
• Treatments: Exenatide; Hypoglycemic Agents; Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Patients have been treated with insulin for >=3 months up to 12 years.

• HbA1c <=10.5%.

• Body mass index (BMI) between 27 kg/m2 and 40 kg/m2.

Exclusion Criteria:

• Patients previously received exenatide or GLP-1 analogs.

• Patients have been treated for greater than 2 weeks with thiazolidinediones or alpha-glucosidase inhibitors within 3 months prior to screening.